Journal: Scientific Reports

Article Title: Mental rotation ability predicts the acquisition of basic endovascular skills

doi: 10.1038/s41598-021-00587-x

Figure Lengend Snippet: High fidelity endovascular simulator. The picture shows the endovascular simulator VIST G5 (Mentice Gothenburg, Sweden), which includes a laptop computer, a human body dummy, a control panel, a syringe for contrast-agent injection, a balloon indeflator and a food paddle to control the simulated X-ray.

Article Snippet: On day one to three, participants individually completed training and test sessions on the simulator VIST G5 (Mentice, Gothenburg, Sweden).

Techniques: Control, Injection

Journal: Scientific Reports

Article Title: Mental rotation ability predicts the acquisition of basic endovascular skills

doi: 10.1038/s41598-021-00587-x

Figure Lengend Snippet: Experimental procedure. On day 0, two computer-based cognitive tests and the Grooved Pegboard were administered. On day one to three, participants individually completed training and test sessions on the simulator VIST G5 (Mentice, Gothenburg, Sweden).

Article Snippet: On day one to three, participants individually completed training and test sessions on the simulator VIST G5 (Mentice, Gothenburg, Sweden).

Techniques:

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: Reporting of review endpoints

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Clinical Proteomics

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: Summary of findings: Tranexamic acid versus placebo

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Comparison, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: Transfusion outcomes for trials of systemic drugs

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Clinical Proteomics

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: Systemic drug treatments

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Comparison

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: Monaco 2020

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Molecular Weight, Filtration, Clinical Proteomics, Sequencing, Selection, Blocking Assay, Generated, Saline, Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: POISE‐3 2022

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Saline, Clinical Proteomics, Sequencing, Selection, Blocking Assay

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: jRCTs041180163

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Control

Journal: The Cochrane Database of Systematic Reviews

Article Title: Drugs to reduce bleeding and transfusion in major open vascular or endovascular surgery: a systematic review and network meta‐analysis

doi: 10.1002/14651858.CD013649.pub2

Figure Lengend Snippet: NCT04803747

Article Snippet: Blinding of participants and personnel (performance bias) All outcomes , Low risk , "Patients randomised to the intervention group received tranexamic acid (Ugurol; Rottapharm S.p.A., Milan, Italy; 0.5 g 5 ml ‐1 vial) according to the following protocol: a loading dose of 500 mg of tranexamic acid diluted in 100 ml saline was intravenously infused slowly 20 min before surgery, and a continuous intravenous infusion of tranexamic acid was then administered at a rate of 250 mg h (2.5 ml h ‐1 , using non‐diluted tranexamic acid contained in the vials) from surgical incision until skin closure. Patients randomised to the control group received placebo (saline) with identical volumes and rates of infusion." "We performed a single‐centre, double‐blinded, parallel‐group, randomised clinical trial".

Techniques: Saline, Biomarker Discovery